Literature Search

Djordjic Crnogorac(M),Karadzic(V),Cato(T),Ca… Int J Mol Sci 2026-07-25

...MSH2 (4.0%) and MSH6 (1.1%), with no PV/LPVs identified in PMS2. Additionally, no pathogenic sequence-level EPCAM varian...

Almperi(EA),Margioula-Siarkou(C),Almperis(A)… Int J Mol Sci 2026-07-31

...MSH2, and MSH6 expression was assessed through immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded hysterect...

Noda(K),Kurohama(H),Matsuda(K),Kinoshita(A),… Pathol Int 2026-08-00

...MSH2 and MSH6 expression in both the extraocular sebaceous carcinoma and the colonic medullary carcinoma. This identical...

Abdel-Razeq(H),Bani Hani(H),Alafeef(S),Tamim… Front Oncol None

...MSH2, MUTYH, BRCA2, and TP53; no BRCA1 P/LP variants were identified. Germline P/LP variants are common in young male pa...

Steenbock(O),Rieger(C),Heidenreich(J),Paffen… Urol Int 2026-08-13

...MSH2, MSH6, PMS2, and MLH1 were analysed. The following databases were reviewed to identify druggable mutations: OncoKB,...

Atarere(J),Bilalaga(MM),Vasireddy(R),Mensah(… Gastro Hep Adv None

...MSH2 carriers (HR: 9.52; 95% CI: [2.32, 39.11]). Among those with adenoma or SSL at first colonoscopy, MSH6 carriers wer...

Durán-Toribio(AK),Jiménez-Díaz(IF),Caballé-P… Crit Rev Oncol Hematol 2026-08-15

...MSH2, PMS2) may support the identification of patients more likely to benefit from immune checkpoint inhibitors, driven ...

Nishibori(S),Sakurai(M),Kagawa(Y),Nishigaki(… Vet Comp Oncol 2026-08-16

...MSH2 and MSH6 antibodies using CRISPR/Cas9-engineered feline tumour cell lines lacking each target gene. Using these val...

Saoud(C),Vanderbilt(C),Benhamida(J),Morris(C… Clin Cancer Res 2026-07-30

...MSH2 and MLH1 predominated in Lynch syndrome-associated cases. TP53 (83%) and NF1 (51%) were frequent somatic co-alterat...

Tang(D),Mao(Z),Lan(S),Song(Y),Chen(S),Chen(Y… Int J Cancer 2026-07-31

...MSH2, and MSH6 were included in the primary analysis. Clinicopathological characteristics and mismatch repair status wer...